Bloods Before Drugs: The MRCP Drug Monitoring Guide

admin
Pharmacy MRCP
1211 words • 5 min read

Article Content

Published by TalkingCases

Nov 16, 2026

Bloods Before Drugs: The MRCP Drug Monitoring Guide

Every MRCP sitting, a predictable family of questions appears: which blood test, how often, and what do you do when it goes wrong? Drug monitoring is one of the highest-yield, lowest-effort areas of the entire syllabus — yet candidates routinely lose these marks because they learn the indications for drugs but never learn the housekeeping around them. This guide turns drug monitoring from a guessing game into guaranteed marks across MRCP Part 1, Part 2 and PACES.


Why Monitoring Questions Are Free Marks

Drug safety and monitoring questions appear in every paper:

  • Part 1 tests baseline investigations (e.g. TPMT before azathioprine), toxic thresholds and pharmacokinetic principles (phenytoin's zero-order kinetics).

  • Part 2 loves the scenario twist: a stable patient on methotrexate develops a cough, a patient on lithium starts naproxen, a heart failure patient is started on spironolactone — what is the single best next action?

  • PACES examiners expect safe prescribing conversations in Stations 2 and 5, and anticipatory care discussions in acute settings.

If you can recite the monitoring schedules below, you bank points in all three.


The Four Rules That Solve Most Monitoring Questions

  1. Baseline before the first dose. TPMT (azathioprine), IGRA/chest X-ray (anti-TNF), retinal OCT (hydroxychloroquine), INR/FBC/U&E/LFT (anticoagulants).

  2. Respect the early danger window. U&E at 1–2 weeks after starting an ACE inhibitor; FBC weekly for 18 weeks on clozapine; U&E at 1 week on spironolactone.

  3. A new interacting drug means recheck. NSAID added to lithium, amiodarone added to warfarin, allopurinol added to azathioprine (never do it).

  4. Symptoms plus drug = stop first, investigate second. Methotrexate pneumonitis, clozapine myocarditis and neutropenia, amiodarone thyrotoxicosis — the exam answer is almost always stop the drug.


The Big Six You Cannot Get Wrong

1. Methotrexate

  • Bloods: FBC, LFTs, U&E.

  • Schedule (BSR): every 2–4 weeks for the first 3 months, every 8–12 weeks for months 3–6, then every 12 weeks long term.

  • Exam pearls: prescribe folic acid at least 5 mg weekly (not on the same day); dry cough + dyspnoea = stop the drug and think pneumonitis; hold during significant infection; teratogenic in both sexes — stop at least 3 months before conception. Once weekly dosing only — fatal errors have occurred with daily dosing.

2. Lithium

  • Levels: 12 hours post-dose; weekly after initiation or dose change until stable, then every 3 months (NICE).

  • Bloods: U&E and TFTs every 6 months; calcium and weight periodically.

  • Toxicity: >1.5 mmol/L stop. Coarse tremor, vomiting, diarrhoea, cerebellar signs, confusion.

  • Interactions that scream exam question: NSAIDs, ACE inhibitors, ARBs, thiazides (reduce lithium clearance); SSRIs and verapamil add toxicity risk.

3. Clozapine

  • The 18–2–1 rule: FBC weekly for 18 weeks, then every 2 weeks until 1 year, then monthly for life.

  • Stop if neutrophils <1.5 ×10⁹/L (benign ethnic neutropenia uses adjusted ranges).

  • Early extras: myocarditis and pericarditis in the first 2 months (troponin if chest pain/flu-like illness), severe constipation, seizure threshold lowering, hypersalivation.

4. Amiodarone

  • Remember TLC: Thyroid function and Liver function every 6 months; annual Chest X-ray (plus ECG and ophthalmology review).

  • Baseline: TFTs, LFTs, U&E, ECG, CXR before starting.

  • Exam pearls: causes both hypo- and hyperthyroidism; pneumonitis; photosensitivity; slate-grey discolouration; corneal microdeposits; massively potentiates warfarin and digoxin.

5. ACE Inhibitors, ARBs and MRA

  • ACEi/ARB: U&E 1–2 weeks after starting and after each dose increase; watch for hyperkalaemia, rising creatinine (small rise acceptable), cough, angio-oedema. Never combine ACEi with ARB.

  • Spironolactone in HFrEF: U&E at 1 week, 1 month, then every 6 months; gynaecomastia — switch to eplerenone if it occurs.

6. Digoxin

  • Target in heart failure: 0.5–0.9 mcg/L; toxicity usually above 2 mcg/L.

  • Toxicity is potentiated by hypokalaemia, hypomagnesaemia, renal impairment, amiodarone, verapamil and macrolides.

  • Clinical picture: nausea, anorexia, confusion, xanthopsia (yellow vision), almost any arrhythmia (classically AV block with increased automaticity).


Specialty Monitoring Tables

Rheumatology and Immunosuppression

Drug Monitoring Exam pearl
Methotrexate FBC, LFT, U&E; 2–4 weekly ×3 months, then 3-monthly Pneumonitis = stop; weekly dosing only
Sulfasalazine FBC, LFT; 2–4 weekly ×3 months, then 3-monthly Reversible oligospermia; orange discolouration
Leflunomide FBC, LFT, BP, weight; as above Long half-life; cholestyramine washout before pregnancy
Hydroxychloroquine Retinal OCT baseline; annual screening after 5 years Screen earlier if >5 mg/kg, eGFR <30, tamoxifen use
Azathioprine TPMT first; then FBC, LFT Never co-prescribe allopurinol
Anti-TNF Exclude TB (IGRA/CXR), hepatitis B/C, HIV Treat latent TB before starting
Rituximab Immunoglobulins before and during Risk of hypogammaglobulinaemia

Psychiatry and Neurology

Drug Monitoring Exam pearl
Lithium Level 3-monthly; U&E/TFT 6-monthly NSAIDs and ACEi push levels up
Clozapine 18–2–1 FBC schedule Neutrophils <1.5 = stop
Sodium valproate LFTs, weight, FBC Neural tube defects; pregnancy prevention programme
Carbamazepine FBC, LFT, sodium Hyponatraemia; HLA-B*1502 (SJS); enzyme inducer — OCP fails
Phenytoin Level 10–20 mg/L Zero-order kinetics — small dose change, big level change
Vigabatrin Visual fields 6-monthly Irreversible visual field constriction
Antipsychotics / methadone ECG (QTc) Additive with macrolides and antiemetics

Cardiology and Anticoagulation

Drug Monitoring Exam pearl
Amiodarone TFT/LFT 6-monthly, annual CXR Thyroid, liver, lungs, eyes, skin
Warfarin INR 2–3 (2.5–3.5 for mechanical valve with risk factors) Amiodarone and antibiotics potentiate
DOACs FBC, U&E (±LFT) at least annually Apixaban 2.5 mg BD if 2 of: age ≥80, weight ≤60 kg, creatinine ≥133
Statins Baseline LFT; CK only if myalgia Routine repeated LFTs not required if baseline normal
Diuretics U&E with intercurrent illness Hyponatraemia with thiazides; hypokalaemia with loops

Anti-infectives

Drug Monitoring Exam pearl
Gentamicin Pre-dose (trough) and post-dose levels Ototoxicity, nephrotoxicity; synergy with furosemide = worse
Vancomycin Trough 10–15 mg/L (15–20 in severe infection) Red man reaction is rate-related, not allergic
Linezolid Weekly FBC Thrombocytopenia with >2 weeks use; serotonin syndrome with SSRIs
Anti-TB therapy Baseline LFTs (RCP); repeat if risk factors Give pyridoxine with isoniazid; ethambutol = colour vision; rifampicin = inducer

Endocrine, Metabolic and Bone

Drug Monitoring Exam pearl
Metformin B12 if long-term use with anaemia/neuropathy; eGFR review Stop if eGFR <30; hold in AKI
SGLT2 inhibitors Renal function review; pause in acute illness, major surgery, prolonged fasting Euglycaemic DKA; genital mycotic infections; Fournier gangrene
Isotretinoin Lipids and LFTs at baseline and 1–2 months Strict pregnancy prevention
Bisphosphonates Correct calcium/vitamin D first; dental assessment Osteonecrosis of the jaw; atypical femoral fractures
Denosumab Calcium and vitamin D before each cycle; never significantly delay doses Rebound vertebral fractures after stopping
Corticosteroids (long-term) BP, glucose/HbA1c, DEXA, growth in children Adrenal suppression; steroid card
Allopurinol Renal function — start low, titrate to target urate HLA-B*5801 (South-East Asian ancestry) — fatal SJS risk

Sick-Day Rules: The Medications to Pause

When a patient develops a dehydrating illness (vomiting, diarrhoea, sepsis), advise pausing the AKI-associated medications:

  • NSAIDs

  • ACE inhibitors and ARBs

  • Diuretics (especially loop + thiazide combinations)

  • Metformin

  • SGLT2 inhibitors (pause during acute serious illness and perioperatively, but do not discontinue long term — their HF/CKD benefits persist)

Also exam favourites: hold methotrexate during significant infection, and never add an NSAID to lithium without checking levels.


QT Prolongation: The ECG Trap

Before starting QT-prolonging drugs — especially in older patients or those on multiple agents — an ECG is the safe answer. The classic list:

  • Antiarrhythmics: amiodarone, sotalol

  • Antibiotics: macrolides, fluoroquinolones

  • Antipsychotics: haloperidol, droperidol

  • Antidepressants: citalopram (dose-capped in the elderly)

  • Antiemeics: domperidone, ondansetron

  • Others: methadone, antimalarials, some antihistamines

If a Part 2 question shows syncope on multiple QT-drugs, think torsades and check the ECG first.


Test Yourself: Three Practice Questions

1. A 66-year-old man with HFrEF (EF 30%) on ramipril, bisoprolol and furosemide is started on spironolactone 25 mg daily. What is the most appropriate blood monitoring?

Answer: U&E at 1 week, again at 1 month, then every 6 months — hyperkalaemia and renal impairment cluster early.

2. A 28-year-old woman is planned to start azathioprine for autoimmune hepatitis. Which test must precede initiation?

Answer: TPMT (thiopurine methyltransferase) activity — low activity predicts profound myelosuppression.

3. A patient with bipolar disorder stable on lithium develops a coarse tremor, vomiting and ataxia two weeks after starting naproxen for back pain. Lithium level 1.9 mmol/L. What is the mechanism?

Answer: NSAIDs reduce renal prostaglandin-mediated lithium excretion, causing toxicity. Management: stop both drugs, IV fluids, urgent psychiatric review.


Memory Hooks That Stick

  • Clozapine: 18–2–1 (weeks → fortnights → monthly, forever)

  • Lithium: 3 and 6 (levels every 3 months, U&E/TFTs every 6 months)

  • Amiodarone: TLC — Thyroid, Liver, Chest X-ray

  • Methotrexate: 2–4–8–12 — the weekly rhythm of monitoring for life

  • Digoxin: under one in heart failure (0.5–0.9 mcg/L)

  • Spironolactone: 1 week, 1 month, 6 months

  • Hydroxychloroquine: screen at 5 (annual eyes after 5 years)

  • Anti-TNF: TB before TNF

  • Azathioprine: TPMT first


The 48-Hour Sweep Before Your Exam

  • Day 1 morning: rewrite the Big Six from memory; recite the rheumatology table.

  • Day 1 afternoon: psychiatry/neurology and cardiology tables; list every lithium interaction you can.

  • Day 2 morning: anti-infectives, endocrine and bone tables; sick-day rules; QT list.

  • Day 2 afternoon: 50 pharmacology questions from your question bank, focusing on monitoring and toxicity stems.

Sources worth quoting in PACES discussions: NICE CG185 (lithium), NICE CG178 (clozapine), BSR methotrexate safety guidelines, RCOphth hydroxychloroquine screening, RCP anti-tuberculosis therapy monitoring, and NICE heart failure guidance for MRA monitoring.


Final Thoughts

Drug monitoring questions reward preparation, not inspiration. The examiner is testing whether you will be a safe prescriber, not just a knowledgeable one. Learn the Big Six cold, skim the tables the night before, and walk into the exam knowing that when a stable patient on a monitored drug suddenly deteriorates, the answer is usually staring at you from this page: stop the drug, check the bloods, and explain to the patient why.

Share

Turn this article into deliberate practice

Reading matters when it leads to action. Move into guided AI practice, open a free account, or continue through related blog content while the topic is still fresh.

Related Articles

Continue your medical education journey with these carefully curated insights

8 min read

Recent Advances in Diabetic Retinopathy: MRCP Ophthalmology Update

Recent Advances in Diabetic Retinopathy: MRCP Ophthalmology UpdateDiabetic retinopathy (DR) remains the leading cause of preventable blindness in working-age adults in the UK — and …

7 min read

AI Practice for MRCP Part 2: Clinical Vignette Mastery

AI Practice for MRCP Part 2: Clinical Vignette MasteryPassing MRCP(UK) Part 1 proves you can recall medicine. Part 2 Written tests something harder: whether you …

6 min read

From MRCP to CESR: The IMG Portfolio Pathway Guide

From MRCP to CESR: The IMG Portfolio Pathway GuidePassing the full MRCP is a landmark achievement — but for many international medical graduates it raises …

Join the Discussion

Share your thoughts and insights with the medical community

Comments